REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia

This phase 2 study (N = 116) evaluated single-agent vosaroxin, a first-in-class anticancer quinolone derivative, in patients ≥60 years of age with previously untreated unfavourable prognosis acute myeloid leukaemia. Dose regimen optimization was explored in sequential cohorts (A: 72 mg/m(2) d 1, 8,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Haematol
Hlavní autoři: Stuart, Robert K, Cripe, Larry D, Maris, Michael B, Cooper, Maureen A, Stone, Richard M, Dakhil, Shaker R, Turturro, Francesco, Stock, Wendy, Mason, James, Shami, Paul J, Strickland, Stephen A, Costa, Luciano J, Borthakur, Gautam, Michelson, Glenn C, Fox, Judith A, Leavitt, Richard D, Ravandi, Farhad
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2015
Témata:
Haematological Malignancy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4354261/
https://ncbi.nlm.nih.gov/pubmed/25403830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13214
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky